Biotech, Financing

CureVac in Series D financing for $80 million

Posted on 19 September 2012

Tags:

CureVac announced the completion of an 80 million financing round with its main investor, dievini Hopp BioTech Holding.

In the next years, CureVac will use the proceeds mainly to advance the development of its two lead RNActive cancer vaccines against prostate cancer and non-small cell lung cancer (NSCLC), respectively.

Additionally, CureVac will intensify the development of its prophylactic vaccines and adjuvants for infectious diseases.

For further deal information visit Current Agreements (subscription required)

 

Related

Read: more on financing deals in pharma, biotech, life science partnering deal news, insights and glossary

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Financing Scorecard – view top life science financing deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard– latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Print Friendly, PDF & Email

Leave a Reply